Study Demonstrates Benefits Of MicroPulse Photocoagulation Over Current Standard Laser Treatment Of Diabetic Macular Edema

IRIDEX Corporation today announced that leading clinicians have performed and published the results of a new study* that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new generation IRIDEX lasers, over the standard-of-care protocol for the treatment of eyes with diabetic macular edema (DME). The results indicated that treating using MicroPulse mode was as effective as the standard-of-care protocol in treating DME but with the added advantages of causing no localized laser scars and significantly improving visual acuity. DME is damage to the retina caused by diabetes, and is the leading cause of blindness in persons under 50 years of age in the developed world. DME affects an estimated 2 million in the U.S. alone.